Published in Diabetologia on March 31, 2010
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Hypoglycemia and cardiovascular risks. Diabetes Care (2011) 1.74
Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia (2010) 1.66
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care (2013) 1.19
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord (2010) 1.14
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther (2013) 1.11
The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care (2011) 0.96
Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care (2012) 0.95
Treatment of type 2 diabetes in youth. Diabetes Care (2011) 0.91
The role of incretin therapy at different stages of diabetes. Rev Diabet Stud (2011) 0.89
The combinatorics of medications precludes evidence-based algorithms for therapy. Diabetologia (2010) 0.88
Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep (2013) 0.88
The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab (2011) 0.86
From authority recommendations to fact-sheets--a future for guidelines. Diabetologia (2010) 0.82
The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with type 2 diabetes mellitus: comparison with the ADA/EASD algorithm. Diabetologia (2010) 0.80
Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med (2014) 0.78
Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis. Diabetes Ther (2013) 0.76
Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. Herz (2016) 0.75
Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: a narrative review. J Diabetes (2014) 0.75
Should the algorithm for the treatment of type 2 diabetes be evidence-based? Diabetologia (2010) 0.75
Insulin therapy. Wien Med Wochenschr (2011) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract (1995) 12.51
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet (2010) 8.27
Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med (2009) 7.08
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 6.40
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med (2007) 6.09
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia (2008) 4.62
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care (2005) 4.58
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 4.57
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia (2006) 3.94
beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev (2007) 3.85
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2007) 3.44
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care (2002) 3.12
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2002) 2.98
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care (2006) 2.98
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol (2009) 2.94
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol (1999) 2.87
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med (2007) 2.76
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin (2009) 2.68
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50
Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst (2006) 2.24
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J (2007) 2.17
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia (2009) 2.16
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf (2007) 2.10
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab (2009) 2.04
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia (2006) 1.89
Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care (1994) 1.79
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf (2008) 1.76
Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes (2009) 1.65
Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care (2008) 1.54
Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab (2001) 1.49
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med (2004) 1.48
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J (2008) 1.47
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab (2008) 1.46
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes (2006) 1.43
The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes (1975) 1.43
Development of evidence-based clinical practice guidelines (CPGs): comparing approaches. Implement Sci (2008) 1.41
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab (2009) 1.40
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab (2004) 1.39
Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther (2008) 1.36
Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf (2008) 1.35
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care (2008) 1.34
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2008) 1.30
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag (2008) 1.27
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med (2005) 1.17
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
PROactive: time for a critical appraisal. Eur Heart J (2008) 1.11
Exenatide and pancreatitis: an update. Expert Opin Drug Saf (2008) 1.04
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab (2004) 0.99
GLP-1 therapy: beyond glucose control. Circ Heart Fail (2008) 0.97
Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab (2007) 0.96
Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol (2007) 0.95
Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med (2005) 0.93
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care (2006) 0.93
Targets and tactics: the relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract (2008) 0.92
Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract (2008) 0.92
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract (2009) 0.89
Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf (2009) 0.87
Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol (2009) 0.86
Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2008) 0.81
Guideline development. Stud Health Technol Inform (2008) 0.81
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther (2007) 0.81
Use of insulin to improve glycemic control in diabetes mellitus. Cardiovasc Drugs Ther (2008) 0.78
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
The DNA sequence of human chromosome 21. Nature (2000) 10.66
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev (1999) 8.21
Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature (1997) 7.33
Oxidative stress and diabetic vascular complications. Diabetes Care (1996) 5.97
Diabetes in identical twins. A study of 200 pairs. Diabetologia (1981) 5.02
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) (1987) 5.01
Regulation of zygotic gene expression in Drosophila primordial germ cells. Curr Biol (1998) 4.53
Oskar organizes the germ plasm and directs localization of the posterior determinant nanos. Cell (1991) 4.33
Induction of germ cell formation by oskar. Nature (1992) 4.23
Determination of anteroposterior polarity in Drosophila. Science (1987) 3.80
The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet (1996) 3.37
Nanos and Pumilio have critical roles in the development and function of Drosophila germline stem cells. Development (1998) 3.16
Translational regulation in development. Cell (1995) 3.13
Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab (2003) 3.10
The Pumilio protein binds RNA through a conserved domain that defines a new class of RNA-binding proteins. RNA (1997) 2.98
Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation (2003) 2.97
A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet (1998) 2.85
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia (2006) 2.82
Abdominal segmentation, pole cell formation, and embryonic polarity require the localized activity of oskar, a maternal gene in Drosophila. Cell (1986) 2.81
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med (2012) 2.80
Radioimmunoassay of prostaglandins Falpha, E1 and E2 in human plasma. Eur J Clin Invest (1975) 2.80
Translational regulation of nanos by RNA localization. Nature (1994) 2.77
Nanos is the localized posterior determinant in Drosophila. Cell (1991) 2.70
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab (2011) 2.68
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care (2000) 2.59
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Localization of nanos RNA controls embryonic polarity. Cell (1992) 2.53
A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum Mol Genet (2001) 2.43
HMG-CoA reductase guides migrating primordial germ cells. Nature (1998) 2.31
Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective. Diabetologia (2010) 2.23
Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. Lancet (2008) 2.21
The function of PS integrins during Drosophila embryogenesis. Cell (1989) 2.19
Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia (2003) 2.18
Regulation of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity in type II hyperlipoproteinaemia. Br Med J (1975) 2.15
A gap gene, hunchback, regulates the spatial expression of Ultrabithorax. Cell (1986) 2.15
Blood cholesterol: who to test. 2. Br J Hosp Med (1992) 2.14
A role of polycomb group genes in the regulation of gap gene expression in Drosophila. Genetics (1994) 2.12
The Drosophila posterior-group gene nanos functions by repressing hunchback activity. Nature (1989) 2.07
Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet (2000) 2.07
Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab (2001) 2.01
Comparative analysis of the Borrelia garinii genome. Nucleic Acids Res (2004) 1.96
The Nifedipine-Total Ischemia Awareness Program: a national survey of painful and painless myocardial ischemia including results of antiischemic therapy. Am J Cardiol (1989) 1.95
Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes (2001) 1.95
Retracted Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest (1979) 1.94
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia (2011) 1.94
hunchback, a gene required for segmentation of an anterior and posterior region of the Drosophila embryo. Dev Biol (1987) 1.90
Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed) (1986) 1.87
Pumilio is essential for function but not for distribution of the Drosophila abdominal determinant Nanos. Genes Dev (1992) 1.85
Improved human islet isolation using a new enzyme blend, liberase. Diabetes (1997) 1.84
Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract (2009) 1.83
Low plasma C4 concentrations: association with microangiopathy in insulin dependent diabetes. Br Med J (Clin Res Ed) (1984) 1.82
Multicentre evaluation of the DCA 2000 system for measuring glycated haemoglobin. DCA 2000 Study Group. Diabetes Metab (1997) 1.82
Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology (1995) 1.77
Chlorpropamide alcohol flushing and diabetic retinopathy. Lancet (1979) 1.72
Spatially restricted activity of a Drosophila lipid phosphatase guides migrating germ cells. Development (2001) 1.72
Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest (1994) 1.72
Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab (1998) 1.72
High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest (1998) 1.71
Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia (2009) 1.70
Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia (2005) 1.69
Genetics of nanos localization in Drosophila. Dev Dyn (1994) 1.68
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism (2002) 1.68
Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol (Oxf) (2001) 1.67
Localization of oskar RNA regulates oskar translation and requires Oskar protein. Development (1995) 1.66
Identification of susceptibility loci for insulin-dependent diabetes mellitus by trans-racial gene mapping. Nature (1989) 1.64
The PUMILIO-RNA interaction: a single RNA-binding domain monomer recognizes a bipartite target sequence. Biochemistry (1999) 1.63
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia (1995) 1.63
Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia (2007) 1.62
Prevalence of symptoms of depression and anxiety in a diabetes clinic population. Diabet Med (2000) 1.61
Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J (2001) 1.60
The fat facets gene is required for Drosophila eye and embryo development. Development (1992) 1.59
A conserved 90 nucleotide element mediates translational repression of nanos RNA. Development (1996) 1.59
The HLA-DPB1--associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1. Diabetes (2001) 1.58
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
Successful stent-graft repair of a vertebrojugular arteriovenous fistula. J Endovasc Ther (2001) 1.57
Paraoxonase gene polymorphisms and sporadic ALS. Neurology (2006) 1.56
Resistin, central obesity, and type 2 diabetes. Lancet (2002) 1.56
Asian patients attending a diabetic clinic. Br Med J (Clin Res Ed) (1985) 1.55
Identification of genes controlling germ cell migration and embryonic gonad formation in Drosophila. Development (1998) 1.54
Germ cell development in Drosophila. Annu Rev Cell Dev Biol (1996) 1.53
Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J (1980) 1.52
Impact of acute hyperglycaemia on endothelial function and retinal vascular reactivity in patients with Type 2 diabetes. Diabet Med (2011) 1.51
Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ (2006) 1.50
Magnetic resonance imaging of a glioblastoma of the optic chiasm. Case report. J Neurosurg (1995) 1.49
A CCHC metal-binding domain in Nanos is essential for translational regulation. EMBO J (1997) 1.49
An Egalitarian-BicaudalD complex is essential for oocyte specification and axis determination in Drosophila. Genes Dev (1997) 1.49
Greece is iodine sufficient. Lancet (2003) 1.48
Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost (2004) 1.48
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia (1998) 1.47
Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia (2007) 1.46
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care (1999) 1.46
Is oxidative stress the missing link between insulin resistance and atherosclerosis? Diabetologia (1995) 1.45
Drug therapy for coronary heart disease: the Sheffield table. Lancet (1998) 1.43
Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med (2007) 1.43
Pregnancy as environmental factor precipitating IDDM. Diabetes Care (1989) 1.43
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
[SFC/ALFEDIAM (French Cardiology Society/French-speaking Association for the Study of Diabetes and Metabolic Diseases) guidelines on the management of the diabetic patient seen by a cardiologist. Recommendations, rationale, references]. Arch Mal Coeur Vaiss (2004) 1.41
Determination of blood flow and endothelial shear stress in human coronary artery in vivo. J Invasive Cardiol (1999) 1.41